Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Benner

Showing results (221-230 of 347) with videos related to

Pageof 35
Sort By:
Journal of Cachexia, Sarcopenia and Muscle|December 13, 2021
Validation of a proxy-reported SARC-F questionnaire for current and retrospective screening of sarcopenia-related functional impairmentsJohannes Maurus, Tobias Terzer, Axel Benner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factorsDirk Kienle, Tiemo Katzenberger, German Ott, et al.
Cancer Research|March 7, 2014
Immune escape and survival mechanisms in circulating tumor cells of colorectal cancerGunnar Steinert, Sebastian Schölch, Thomas Niemietz, et al.
European Journal of Haematology|September 24, 2017
Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patientsSabine Kayser, Maximilian Feszler, Julia Krzykalla, et al.
Frontiers in Immunology|June 8, 2026
Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxisConrad Weidt, Adela Maria Neagoie, Maral Saadati, et al.
Blood Cancer Journal|April 10, 2019
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trialKatja C Weisel, Christof Scheid, Manola Zago, et al.
Human Molecular Genetics|August 9, 2014
p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomasDaniel Dreidax, Steffen Bannert, Kai-Oliver Henrich, et al.
Blood|February 29, 2020
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuriaChristoph R Kimmich, Tobias Terzer, Axel Benner, et al.
Haematologica|May 20, 2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow upUte Hegenbart, Tilmann Bochtler, Axel Benner, et al.
Experimental and Molecular Pathology|July 24, 2021
The coding microsatellite mutation profile of PMS2-deficient colorectal cancerSanne W Bajwa-Ten Broeke, Alexej Ballhausen, Aysel Ahadova, et al.
Pageof 35

Showing results (221-230 of 347) with videos related to

Sort By:
Pageof 35
Journal of Cachexia, Sarcopenia and Muscle|December 13, 2021
Validation of a proxy-reported SARC-F questionnaire for current and retrospective screening of sarcopenia-related functional impairmentsJohannes Maurus, Tobias Terzer, Axel Benner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factorsDirk Kienle, Tiemo Katzenberger, German Ott, et al.
Cancer Research|March 7, 2014
Immune escape and survival mechanisms in circulating tumor cells of colorectal cancerGunnar Steinert, Sebastian Schölch, Thomas Niemietz, et al.
European Journal of Haematology|September 24, 2017
Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patientsSabine Kayser, Maximilian Feszler, Julia Krzykalla, et al.
Frontiers in Immunology|June 8, 2026
Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxisConrad Weidt, Adela Maria Neagoie, Maral Saadati, et al.
Blood Cancer Journal|April 10, 2019
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trialKatja C Weisel, Christof Scheid, Manola Zago, et al.
Human Molecular Genetics|August 9, 2014
p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomasDaniel Dreidax, Steffen Bannert, Kai-Oliver Henrich, et al.
Blood|February 29, 2020
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuriaChristoph R Kimmich, Tobias Terzer, Axel Benner, et al.
Haematologica|May 20, 2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow upUte Hegenbart, Tilmann Bochtler, Axel Benner, et al.
Experimental and Molecular Pathology|July 24, 2021
The coding microsatellite mutation profile of PMS2-deficient colorectal cancerSanne W Bajwa-Ten Broeke, Alexej Ballhausen, Aysel Ahadova, et al.
Pageof 35